[Translation] A single-center, open-label, randomized, single-dose, two-period, two-sequence, crossover bioequivalence trial evaluating the investigational formulation letrozole tablets (2.5 mg) versus the reference formulation letrozole tablets (Femara®, 2.5 mg) in healthy adult trial participants in fasting condition.
主要试验目的:研究空腹状态下单次口服受试制剂来曲唑片(规格:2.5 mg,Shin Poong Pharm. Co., Ltd.持证、Shin Poong Pharm. Co., Ltd.生产)与参比制剂来曲唑片(Femara®,规格:2.5 mg,Novartis Pharma Schweiz AG持证、Novartis Pharma Stein AG生产)在健康成年试验参与者体内的药代动力学,评价空腹状态下口服两种制剂的生物等效性。
次要试验目的:评估受试制剂来曲唑片(规格:2.5 mg)和参比制剂来曲唑片(Femara®,规格:2.5 mg)在健康成年试验参与者中的安全性。
[Translation] Primary objective: To investigate the pharmacokinetics of a single oral dose of the test formulation letrozole tablets (2.5 mg, licensed and manufactured by Shin Poong Pharm. Co., Ltd.) and the reference formulation letrozole tablets (Femara®, 2.5 mg, licensed and manufactured by Novartis Pharma Schweiz AG) in healthy adult participants under fasting conditions, and to evaluate the bioequivalence of the two formulations under fasting conditions.
Secondary objective: To assess the safety of the test formulation letrozole tablets (2.5 mg) and the reference formulation letrozole tablets (Femara®, 2.5 mg) in healthy adult participants.